ABCG2 and cancer: Reduced ABCG2 expression as consequence of the presence of SNP c.421C>A (p.Gln141Lys) was associated with an adverse response to cancer chemotherapy, but its pharmacogenomic effect appears to be dependent on substrate and correlated with its genotype [6,15] which has been also well summarized recently elsewhere [23,44].